Shaping the future of AI/ML in pharmacometrics through collaboration, education and best practices Poster Shaping the future of AI/ML in pharmacometrics through collaboration, education and best practices Discover how the AI/ML Special Interest Group is advancing responsible artificial intelligence in pharmacometrics through…CertaraJune 22, 2026
Machine Learning based drug renal clearance predictor development and application Poster Machine Learning based drug renal clearance predictor development and application A machine learning QSAR model predicts human renal clearance from simple, easy-to-obtain inputs and sharpens…CertaraJune 22, 2026
Accelerating QSP Virtual Population Generation Through Active Learning and Bayesian Optimization Poster Accelerating QSP Virtual Population Generation Through Active Learning and Bayesian Optimization Discover how active learning and Bayesian optimization improve virtual population generation for quantitative systems pharmacology…CertaraJune 18, 2026
Building IND-Ready and Investor-Ready Development Programs On-Demand Webinar Building IND-Ready and Investor-Ready Development Programs Learn how emerging biotechs can build IND-ready, investor-ready development programs using Totality of Evidence, NAMs,…CertaraJune 15, 2026
2026 Simcyp Workshops Brochure 2026 Simcyp Workshops Advance your PBPK and model-informed drug development expertise with Simcyp workshops. Learn from experts through…CertaraJune 11, 2026
Translating Targeted Radiotherapies from Mouse to Human Using QSP: A Pluvicto Case Study Poster Translating Targeted Radiotherapies from Mouse to Human Using QSP: A Pluvicto Case Study Download this poster to see how Certara used quantitative systems pharmacology (QSP) to translate ¹⁷⁷Lu-PSMA-617…CertaraJune 9, 2026
Population Pharmacokinetic Modeling to Predict Absorbed and Biologically Effective Dose for Radioligand Therapies Poster Population Pharmacokinetic Modeling to Predict Absorbed and Biologically Effective Dose for Radioligand Therapies Explore how population PK modeling predicts absorbed dose and biologically effective dose for radioligand therapies.CertaraJune 9, 2026
Beyond compliance: What ICH M15 means for the future of drug development Blog Beyond compliance: What ICH M15 means for the future of drug development Explore how ICH M15 is shaping regulatory expectations for Model-Informed Drug Development (MIDD), including model…CertaraJune 9, 2026
Applying AI-Driven Biosimulation to Drug Discovery Video Applying AI-Driven Biosimulation to Drug Discovery Certara President Leif Pedersen explains how PBPK and QSP modeling, proven across 125+ FDA-approved drugs,…CertaraJune 2, 2026
Model Acceptance in Regulatory Submissions: Practical Strategies for Regulatory Success Webinar Model Acceptance in Regulatory Submissions: Practical Strategies for Regulatory Success CertaraJune 1, 2026